Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-1|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-2|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-3|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-4|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-5|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-6|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-7|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-8|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-9|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-10|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-11|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-12|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-13|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-14|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-15|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-16|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-17|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-18|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-19|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-20|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-21|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-22|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-23|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-24|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-25|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-26|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-27|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-28|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-29|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-30|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-31|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-32|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-33|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-34|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-35|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-36|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-37|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-38|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-39|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-40|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-41|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-42|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-43|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-44|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-45|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-46|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-47|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-48|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-1|n/a,STC KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-1-49|1|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-1|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-2|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-3|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-4|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-5|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-6|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-7|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-8|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-9|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-10|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-11|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-12|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-13|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-14|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-15|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-16|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-17|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-18|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-19|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-20|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-21|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-22|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-23|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-24|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-25|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-26|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-27|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-28|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-29|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-30|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-31|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-32|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-33|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-34|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-35|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-36|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-37|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-38|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-39|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-40|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-41|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-42|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-43|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-44|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-45|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-46|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-47|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-48|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-49|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-2|n/a,STC S|1|28|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject. over 4 w|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-2-50|2|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-1|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-2|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-3|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-4|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-5|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-6|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-7|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-8|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-9|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-10|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-11|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-12|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-13|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-14|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-15|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-16|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-17|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-18|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-19|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-20|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-21|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-22|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-23|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-24|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-25|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-26|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-27|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-28|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-29|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-30|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-31|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-32|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-33|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-34|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-35|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-36|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-37|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-38|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-39|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-40|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-41|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-42|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-43|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-44|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-45|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-46|3|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-47|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-3|n/a,STC 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-3-48|3|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-1|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-2|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-3|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-4|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-5|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-6|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-7|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-8|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-9|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-10|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-11|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-12|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-13|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-14|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-15|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-16|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-17|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-18|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-19|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-20|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-21|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-22|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-23|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-24|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-25|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-26|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-27|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-28|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-29|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-30|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-31|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-32|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-33|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-34|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-35|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-36|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-37|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-38|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-39|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-40|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-41|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-42|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-43|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-44|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-45|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-46|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-47|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-48|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-1|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-2|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-3|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-4|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-5|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-6|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-7|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-8|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-9|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-10|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-11|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-12|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-13|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-14|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-15|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-16|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-17|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-18|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-19|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-20|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-21|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-22|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-23|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-24|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-25|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-26|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-27|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-28|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-29|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-30|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-31|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-32|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-33|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-34|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-35|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-36|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-37|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-38|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-39|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-40|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-41|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-42|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-43|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-44|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-45|4|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-46|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-47|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-4|n/a,STS 5S|2|56|lipopolysaccharide (LPS)|160|micrograms|Injection, intraperitoneal|in 8 inject over 4 w|48 (48 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcomas only|5-8-4-48|4|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-1|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-2|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-3|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-4|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-5|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-6|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-7|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-8|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-9|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-10|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-11|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-12|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-13|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-14|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-15|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-16|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-17|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-18|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-19|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-20|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-21|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-22|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-23|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-24|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-25|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-26|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-27|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-28|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-29|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-30|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-31|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-32|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-33|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-34|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-35|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-36|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-37|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-38|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-39|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-40|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-41|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-42|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-43|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-44|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-45|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-46|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-47|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-48|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-49|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-5|n/a,STE KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-5-50|5|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-1|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-2|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-3|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-4|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-5|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-6|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-7|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-8|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-9|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-10|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-11|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-12|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-13|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-14|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-15|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-16|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-17|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-18|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-19|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-20|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-21|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-22|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-23|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-24|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-25|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-26|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-27|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-28|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-29|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-30|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-31|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-32|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-33|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-34|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-35|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-36|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-37|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-38|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-39|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-40|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-41|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-42|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-43|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-44|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-45|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-46|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-47|6|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-6|n/a,STE 5|1|56|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-6-48|6|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-1|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-2|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-3|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-4|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-5|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-6|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-7|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-8|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-9|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-10|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-11|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-12|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-13|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-14|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-15|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-16|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-17|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-18|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-19|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-20|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-21|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-22|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-23|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-24|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-25|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-26|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-27|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-28|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-29|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-30|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-1|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-2|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-3|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-4|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-5|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-6|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-7|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-8|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-9|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-10|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-11|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-12|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-13|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-14|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-15|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-16|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-17|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-18|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-19|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-20|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-21|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-22|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-23|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-24|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-25|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-26|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-27|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-28|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-29|7|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-7|n/a,STE S5|2|56|lipopolysaccharide (LPS)|320|micrograms|Injection, intraperitoneal|in 16 inject over 8 w|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcomas only|5-8-7-30|7|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-1|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-2|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-3|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-4|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-5|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-6|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-7|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-8|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-9|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-10|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-11|8|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-12|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-13|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-14|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-15|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-16|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-17|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-18|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-19|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-20|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-21|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-22|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-23|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-24|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-25|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-26|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-27|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-28|8|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-29|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-30|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-31|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-32|8|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-33|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-34|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-35|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-36|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-37|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-38|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-39|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-40|8|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-41|8|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-42|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-43|8|1|n/a|n/a|n/a|
5-8-8|n/a,TPA KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|44 (44 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-8-44|8|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-1|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-2|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-3|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-4|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-5|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-6|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-7|9|1|n/a|n/a|n/a|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-8|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-9|9|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-10|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-11|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-12|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-13|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-14|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-15|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-16|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-17|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-18|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-19|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-20|9|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-21|9|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-22|9|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-23|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-24|9|1|n/a|n/a|n/a|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-25|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-26|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-27|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-28|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-29|9|1|n/a|n/a|n/a|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-30|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-31|9|1|n/a|n/a|n/a|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-32|9|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-33|9|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-34|9|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-9|n/a,TPA P1|1|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6x/w|35 (35 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-9-35|9|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-1|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-2|10|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-3|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-4|10|1|n/a|n/a|n/a|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-5|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-6|10|1|n/a|n/a|n/a|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-7|10|1|n/a|n/a|n/a|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-8|10|1|n/a|n/a|n/a|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-9|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-10|10|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-11|10|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-12|10|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-13|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-14|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-15|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-16|10|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-17|10|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-18|10|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-19|10|1|n/a|n/a|n/a|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-20|10|1|n/a|n/a|n/a|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-21|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-22|10|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-23|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-24|10|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-25|10|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-26|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-27|10|1|n/a|n/a|n/a|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-28|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-29|10|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-10|n/a,TPA P2|1|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (30 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-10-30|10|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-1|11|1|n/a|n/a|n/a|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-2|11|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-3|11|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-4|11|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-5|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-6|11|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-7|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-8|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-9|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-10|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-11|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-12|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-13|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-14|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-15|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-16|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-17|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-18|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-19|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-20|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-21|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-22|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-23|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-24|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-25|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-26|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-27|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-28|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-29|11|1|n/a|n/a|n/a|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-30|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-31|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-32|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-33|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-34|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-35|11|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-36|11|1|n/a|n/a|n/a|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-37|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-38|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-39|11|1|n/a|n/a|n/a|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-40|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-41|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-42|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-43|11|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-44|11|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-45|11|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-46|11|1|n/a|n/a|n/a|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-47|11|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-48|11|1|n/a|n/a|n/a|
5-8-11|n/a,TPA T|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-11-49|11|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-1|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-2|12|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-3|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-4|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-5|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-6|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-7|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-8|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-9|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-10|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-11|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-12|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-13|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-14|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-15|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-16|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-17|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-18|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-19|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-20|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-21|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-22|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-23|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-24|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-25|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-26|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-27|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-28|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-29|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-30|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-31|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-32|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-33|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-34|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-35|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-36|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-37|12|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-38|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-39|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-40|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-1|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-2|12|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-3|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-4|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-5|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-6|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-7|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-8|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-9|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-10|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-11|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-12|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-13|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-14|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-15|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-16|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-17|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-18|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-19|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-20|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-21|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-22|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-23|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-24|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-25|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-26|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-27|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-28|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-29|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-30|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-31|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-32|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-33|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-34|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-35|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-36|12|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-37|12|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-38|12|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-39|12|1|n/a|n/a|n/a|
5-8-12|n/a,TPA T-P1|2|230|ALP alkyl-phospholipid|10|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-12-40|12|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-1|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-2|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-3|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-4|13|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-5|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-6|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-7|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-8|13|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-9|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-10|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-11|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-12|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-13|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-14|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-15|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-16|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-17|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-18|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-19|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-20|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-21|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-22|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-23|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-24|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-25|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-26|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-27|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-28|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-29|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-30|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-31|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-32|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-33|13|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-34|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-35|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-36|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-37|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-38|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-39|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|1|28|Th-227 citrate|222|becquerels per g animal|Injection, intraperitoneal|6 inj over 12 w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-40|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-1|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-2|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-3|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-4|13|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-5|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-6|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-7|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-8|13|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-9|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-10|13|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-11|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-12|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-13|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-14|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-15|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-16|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-17|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-18|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-19|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-20|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-21|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-22|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-23|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-24|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-25|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-26|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-27|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-28|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-29|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-30|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-31|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-32|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-33|13|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-34|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-35|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-36|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-37|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-38|13|1|n/a|n/a|n/a|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-39|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-13|n/a,TPA`T-P2|2|230|ALP alkyl-phospholipid|20|milligrams per kg per day|Ingestion in food or water|from day 280-800 6X/w|40 (40 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-13-40|13|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-1|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-2|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-3|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-4|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-5|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-6|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-7|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-8|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-9|14|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-10|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-11|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-12|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-13|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-14|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-15|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-16|14|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-17|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-18|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-19|14|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-20|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-21|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-22|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-23|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-24|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-25|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-26|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-27|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-28|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-29|14|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-30|14|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-31|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-32|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-33|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-34|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-35|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-36|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-37|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-38|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-39|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-40|14|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-41|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-42|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-43|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-44|14|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-45|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-46|14|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-47|14|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-48|14|1|n/a|n/a|n/a|
5-8-14|n/a,TP KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-14-49|14|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-1|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-2|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-3|15|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-4|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-5|15|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-6|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-7|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-8|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-9|15|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-10|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-11|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-12|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-13|15|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-14|15|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-15|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-16|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-17|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-18|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-19|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-20|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-21|15|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-22|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-23|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-24|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-25|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-26|15|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-27|15|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-28|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-29|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-30|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-31|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-32|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-33|15|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-34|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-35|15|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-36|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-37|15|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-38|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-39|15|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-40|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-41|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-42|15|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-43|15|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-44|15|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-45|15|1|n/a|n/a|n/a|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-46|15|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-15|n/a,TP 5|1|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-15-47|15|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-1|16|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-2|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-3|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-4|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-5|16|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-6|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-7|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-8|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-9|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-10|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-11|16|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-12|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-13|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-14|16|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-15|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-16|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-17|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-18|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-19|16|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-20|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-21|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-22|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-23|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-24|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-25|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-26|16|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-27|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-28|16|1|Neoplasia systemic|Haematolymphatic system|L|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-29|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-30|16|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-31|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-32|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-33|16|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-34|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-35|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-36|16|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-37|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-38|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-39|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-40|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-41|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-42|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-43|16|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-44|16|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-45|16|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-46|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-47|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-48|16|1|n/a|n/a|n/a|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-49|16|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-16|n/a,TP P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-16-50|16|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-1|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-2|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-3|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-4|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-5|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-6|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-7|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-8|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-9|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-10|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-11|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-12|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-13|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-14|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-15|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-16|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-17|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-18|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-19|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-20|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-21|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-22|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-23|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-24|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-25|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-26|17|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-27|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-28|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-29|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-30|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-31|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-32|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-33|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-34|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-35|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-36|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-37|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-38|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-39|17|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-40|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-41|17|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-42|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-43|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-44|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone|b,MPATH: 218 - neoplasm|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-45|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-46|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-47|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-48|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-49|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-1|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-2|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-3|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-4|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-5|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-6|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-7|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-8|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-9|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-10|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-11|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-12|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-13|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-14|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-15|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-16|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-17|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-18|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-19|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-20|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-21|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-22|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-23|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-24|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-25|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-26|17|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-27|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-28|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-29|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-30|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-31|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-32|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-33|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-34|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-35|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-36|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-37|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-38|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-39|17|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-40|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-41|17|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-42|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-43|17|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-44|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone|b,MPATH: 218 - neoplasm|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-45|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-46|17|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-47|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-48|17|1|n/a|n/a|n/a|
5-8-17|n/a,TP 5  P|2|122|ALP alkyl-phospholipid|50|micrograms|Ingestion in food or water|from day 122-207 afterwards 100g|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-17-49|17|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-1|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-2|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-3|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-4|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-5|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-6|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-7|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-8|18|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-9|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-10|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-11|18|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-12|18|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-13|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-14|18|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-15|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-16|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-17|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-18|18|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-19|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-20|18|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-21|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-22|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-23|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-24|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-25|18|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-26|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-27|18|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-28|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-29|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-30|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-31|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-32|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-33|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-34|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-35|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-36|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-37|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-38|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-39|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-40|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-41|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-42|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-43|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-44|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-45|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-46|18|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-47|18|1|n/a|n/a|n/a|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-48|18|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-49|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-18|n/a,LHC KO|1|42|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-18-50|18|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-1|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-2|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-3|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-4|19|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-5|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-6|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-7|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-8|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-9|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-10|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-11|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-12|19|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-13|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-14|19|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-15|19|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-16|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-17|19|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-18|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-19|19|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-20|19|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-21|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-22|19|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-23|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-24|19|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-25|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-26|19|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-27|19|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-28|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-29|19|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-30|19|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-31|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-32|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-33|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-34|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-35|19|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-36|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-37|19|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-38|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-39|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-40|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-41|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-42|19|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-43|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-44|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-45|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-46|19|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-47|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-48|19|1|n/a|n/a|n/a|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-49|19|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-19|n/a,LHC B|1|154|-aminopropionitrile|2.5|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-19-50|19|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-1|20|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-2|20|1|n/a|n/a|n/a|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-3|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-4|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-5|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-6|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-7|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-8|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-9|20|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-10|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-11|20|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-12|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-13|20|1|n/a|n/a|n/a|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-14|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-15|20|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-16|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-17|20|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-18|20|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-19|20|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-20|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-21|20|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-22|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-23|20|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-24|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-25|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-26|20|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-27|20|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-28|20|1|n/a|n/a|n/a|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-29|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-30|20|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-31|20|1|n/a|n/a|n/a|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-32|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-33|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-34|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-35|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-36|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-37|20|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-38|20|1|n/a|n/a|n/a|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-39|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-40|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-41|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-42|20|1|n/a|n/a|n/a|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-43|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-44|20|1|n/a|n/a|n/a|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-45|20|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-46|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-47|20|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-48|20|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-20|n/a,LHC 5|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-20-49|20|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-1|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-2|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-3|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-4|21|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-5|21|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-6|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-7|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-8|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-9|21|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-10|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-11|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-12|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-13|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-14|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-15|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-16|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-17|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-18|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-19|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-20|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-21|21|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-22|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-23|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-24|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-25|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-26|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-27|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-28|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-29|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-30|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-31|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-32|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-33|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-34|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-35|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-36|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-37|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-38|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-39|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-40|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-41|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-42|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-43|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-44|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-45|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-46|21|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-47|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-48|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-49|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-21|n/a,LHC 5B|1|42|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-50|21|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-1|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-2|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-3|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-4|21|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-5|21|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-6|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-7|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-8|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-9|21|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-10|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-11|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-12|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-13|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-14|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-15|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-16|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-17|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-18|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-19|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-20|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-21|21|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-22|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-23|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-24|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-25|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-26|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-27|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-28|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-29|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-30|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-31|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-32|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-33|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-34|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-35|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-36|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-37|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-38|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-39|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-40|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-41|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-42|21|1|n/a|n/a|n/a|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-43|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-44|21|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-45|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-46|21|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-47|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-48|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-49|21|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-21|n/a,LHC 5B|2|154|-aminopropionitrile|2|milligrams per g food|Ingestion in food or water|during 5, 7, 9, 11, 13, 14, 17th month of life|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-21-50|21|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-1|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-2|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-3|22|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-4|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-5|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-6|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-7|22|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-8|22|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-9|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-10|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-11|22|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-12|22|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-13|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-14|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-15|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-16|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-17|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-18|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-19|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-20|22|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-21|22|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-22|22|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.-lymphatic leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-23|22|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-24|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-25|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-26|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-27|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-28|22|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-29|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-30|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-31|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-32|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-33|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-34|22|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-35|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-36|22|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-37|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-38|22|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-39|22|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-40|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-41|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-42|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-43|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-44|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-45|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-46|22|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-47|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-48|22|1|n/a|n/a|n/a|
5-8-22|n/a,CDB KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-22-49|22|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-1|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-2|23|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-3|23|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-4|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-5|23|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-6|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-7|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-8|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-9|23|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-10|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-11|23|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-12|23|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-13|23|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-14|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-15|23|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-16|23|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-17|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-18|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-19|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-20|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-21|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-22|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-23|23|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-24|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-25|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-26|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-27|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-28|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-29|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-30|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-31|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-32|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-33|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-34|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-35|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-36|23|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-37|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-38|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-39|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-40|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-41|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-42|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-43|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-44|23|1|n/a|n/a|n/a|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-45|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-46|23|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-47|23|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-48|23|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-23|n/a,CDB C|1|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-23-49|23|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-1|24|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-2|24|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-3|24|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-4|24|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-5|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-6|24|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-7|24|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-8|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-9|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-10|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-11|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-12|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-13|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-14|24|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-15|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-16|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-17|24|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-18|24|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-19|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-20|24|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-21|24|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-22|24|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-23|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-24|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-25|24|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-26|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-27|24|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-28|24|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-29|24|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-30|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-31|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-32|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-33|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-34|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-35|24|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-36|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-37|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-38|24|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-39|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-40|24|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-41|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-42|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-43|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-44|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-45|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-46|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-47|24|1|n/a|n/a|n/a|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-48|24|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-24|n/a,CDB 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|101|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-24-49|24|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-1|25|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-2|25|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-3|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-4|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-5|25|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-6|25|1|n/a|n/a|n/a|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-7|25|1|n/a|n/a|n/a|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-8|25|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-9|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-10|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-11|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-12|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-13|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-14|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-15|25|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-16|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-17|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-18|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-19|25|1|n/a|n/a|n/a|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-20|25|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-21|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-22|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-23|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-24|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-25|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-26|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-27|25|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-28|25|1|n/a|n/a|n/a|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-29|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-30|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-31|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-32|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-33|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-34|25|1|n/a|n/a|n/a|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-35|25|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-36|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-37|25|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-38|25|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-39|25|1|Neoplasia benign|Bone among musculo-skeletal system diseases|b|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-40|25|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-41|25|1|n/a|n/a|n/a|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-42|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-43|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-44|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-45|25|1|n/a|n/a|n/a|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-46|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-47|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-48|25|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-49|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-25|n/a,CDB 5C|2|154|cadmium chloride|25|parts per million|Ingestion in food or water|from day 154 - 305|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|full pathology|5-8-25-50|25|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-1|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-2|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-3|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-4|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-5|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-6|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-7|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-8|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-9|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-10|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-11|26|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-12|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-13|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-14|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-15|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-16|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-17|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-18|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-19|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-20|26|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-21|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-22|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-23|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-24|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-25|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-26|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-27|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-28|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-29|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-30|26|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-31|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-32|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-33|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-34|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-35|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-36|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-37|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-38|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-39|26|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-40|26|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-41|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-42|26|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-43|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-44|26|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-45|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-46|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-47|26|1|n/a|n/a|n/a|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-48|26|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-49|26|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-26|n/a,TA KO|1|84|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-26-50|26|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-1|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-2|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-3|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-4|27|1|n/a|n/a|n/a|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-5|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-6|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-7|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-8|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-9|27|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-10|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-11|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-12|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-13|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-14|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-15|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-16|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-17|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-18|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-19|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-20|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-21|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-22|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-23|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-24|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-25|27|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-26|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-27|27|1|n/a|n/a|n/a|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-28|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-29|27|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-30|27|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-31|27|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-32|27|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-33|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-34|27|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-35|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-36|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-37|27|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-38|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-39|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-40|27|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-41|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-42|27|1|n/a|n/a|n/a|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-43|27|1|n/a|n/a|n/a|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-44|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-45|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-46|27|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-47|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-48|27|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-49|27|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-27|n/a,TA A|1|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-27-50|27|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-1|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-2|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-3|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-4|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-5|28|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-6|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-7|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-8|28|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-9|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-10|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-11|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-12|28|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-13|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-14|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-15|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-16|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-17|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-18|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-19|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-20|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-21|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-22|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-23|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-24|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-25|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-26|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-27|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-28|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-29|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-30|28|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-31|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-32|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-33|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-34|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-35|28|1|n/a|n/a|n/a|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-36|28|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-37|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-38|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-39|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-40|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-41|28|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-42|28|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-43|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-44|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-45|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-46|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-47|28|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-48|28|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-28|n/a,TA 5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-28-49|28|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-1|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-2|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-3|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-4|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-5|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-6|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-7|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-8|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-9|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-10|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-11|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-12|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-13|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-14|29|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-15|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-16|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-17|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-18|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-19|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-20|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-21|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-22|29|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-23|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-24|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-25|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-26|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-27|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-28|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-29|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-30|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-31|29|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-32|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-33|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-34|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-35|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-36|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-37|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-38|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-39|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-40|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-41|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-42|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-43|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-44|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-45|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-46|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|1|84|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-47|29|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-1|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-2|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-3|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-4|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-5|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-6|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-7|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-8|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-9|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-10|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-11|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-12|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-13|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-14|29|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-15|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-16|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-17|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-18|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-19|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-20|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-21|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-22|29|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-23|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-24|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-25|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-26|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-27|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-28|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-29|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-30|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-31|29|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-32|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-33|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-34|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-35|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-36|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-37|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-38|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-39|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-40|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-41|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-42|29|1|n/a|n/a|n/a|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-43|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-44|29|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-45|29|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-46|29|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-29|n/a,TA A5|2|79|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|for 3 days prior radioactivity|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-29-47|29|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-1|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-2|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-3|30|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-4|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-5|30|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-6|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-7|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-8|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-9|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-10|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-11|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-12|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-13|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-14|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-15|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-16|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-17|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-18|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-19|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-20|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-21|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-22|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-23|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-24|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-25|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-26|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-27|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-28|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-29|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-30|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-31|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-32|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-33|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-34|30|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-35|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-36|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-37|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-38|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-39|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-40|30|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-41|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-42|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-43|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-44|30|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-45|30|1|n/a|n/a|n/a|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-46|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-47|30|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-48|30|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-49|30|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-30|n/a,TAB KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-30-50|30|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-1|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-2|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-3|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-4|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-5|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-6|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-7|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-8|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-9|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-10|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-11|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-12|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-13|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-14|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-15|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-16|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-17|31|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-18|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-19|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-20|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-21|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-22|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-23|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-24|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-25|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-26|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-27|31|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-28|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-29|31|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-30|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-31|31|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-32|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-33|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-34|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-35|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-36|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-37|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-38|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-39|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-40|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-41|31|1|n/a|n/a|n/a|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-42|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-43|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-44|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-45|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-46|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-47|31|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-48|31|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-49|31|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-31|n/a,TAB A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-31-50|31|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-1|32|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-2|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-3|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-4|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-5|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-6|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-7|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-8|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-9|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-10|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-11|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-12|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-13|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-14|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-15|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-16|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-17|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-18|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-19|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-20|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-21|32|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-22|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-23|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-24|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-25|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-26|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-27|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-28|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-29|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-30|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-31|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-32|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-33|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-34|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-35|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-36|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-37|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-38|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-39|32|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-40|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-41|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-42|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-43|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-44|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-45|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-46|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-47|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-48|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-49|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-50|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-51|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-52|32|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-53|32|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-54|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-55|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-56|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-57|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-58|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-59|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-60|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-61|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-62|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-63|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-64|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-65|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-66|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-67|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-68|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-69|32|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-70|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-71|32|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-72|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-73|32|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-74|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-75|32|1|n/a|n/a|n/a|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-76|32|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-77|32|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-78|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-79|32|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-32|n/a,TAB 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-32-80|32|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-1|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-2|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-3|33|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-4|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-5|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-6|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-7|33|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-8|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-9|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-10|33|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-11|33|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-12|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-13|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-14|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-15|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-16|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-17|33|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-18|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-19|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-20|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-21|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-22|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-23|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-24|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-25|33|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-26|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-27|33|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-28|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-29|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-30|33|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-31|33|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-32|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-33|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-34|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-35|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-36|33|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-37|33|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-38|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-39|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-40|33|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-41|33|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-42|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-43|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-44|33|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-45|33|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-46|33|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-47|33|1|n/a|n/a|n/a|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-48|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-49|33|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-50|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-51|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-52|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-53|33|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-54|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-55|33|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-56|33|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-57|33|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-33|n/a,TAB 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-33-58|33|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-1|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-2|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-3|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-4|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-5|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-6|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-7|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-8|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-9|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-10|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-11|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-12|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-13|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-14|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-15|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-16|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-17|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-18|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-19|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-20|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-21|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-22|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-23|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-24|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-25|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-26|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-27|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-28|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-29|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-30|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-31|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-32|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-33|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-34|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-35|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-36|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-37|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-38|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-39|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-40|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-41|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-42|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-43|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-44|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-45|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-46|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-47|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-48|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-49|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-50|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-51|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-52|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-53|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-54|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-55|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-56|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-57|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-58|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-59|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-60|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-61|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-62|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-63|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-64|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-65|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-66|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-67|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-68|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-69|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-70|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-71|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-72|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-73|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-74|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-75|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-76|34|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-1|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-2|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-3|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-4|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-5|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-6|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-7|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-8|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-9|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-10|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-11|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-12|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-13|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-14|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-15|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-16|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-17|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-18|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-19|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-20|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-21|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-22|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-23|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-24|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-25|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-26|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-27|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-28|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-29|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-30|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-31|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-32|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-33|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-34|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-35|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-36|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-37|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-38|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-39|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-40|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-41|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-42|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-43|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-44|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-45|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-46|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-47|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-48|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-49|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-50|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-51|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-52|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-53|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-54|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-55|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-56|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-57|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-58|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-59|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-60|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-61|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-62|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-63|34|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-64|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-65|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-66|34|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-67|34|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-68|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-69|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-70|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-71|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-72|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-73|34|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-74|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-75|34|1|n/a|n/a|n/a|
5-8-34|n/a,TAB 1A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|76 (76 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-34-76|34|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-1|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-2|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-3|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-4|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-5|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-6|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-7|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-8|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-9|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-10|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-11|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-12|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-13|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-14|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-15|35|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-16|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-17|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-18|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-19|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-20|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-21|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-22|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-23|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-24|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-25|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-26|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-27|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-28|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-29|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-30|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-31|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-32|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-33|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-34|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-35|35|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-36|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-37|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-38|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-39|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-40|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-41|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-42|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-43|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-44|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-45|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-46|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-47|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-48|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-49|35|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-50|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-51|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-52|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-53|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-54|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-55|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-56|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-57|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-58|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-1|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-2|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-3|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-4|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-5|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-6|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-7|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-8|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-9|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-10|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-11|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-12|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-13|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-14|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-15|35|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-16|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-17|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-18|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-19|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-20|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-21|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-22|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-23|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-24|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-25|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-26|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-27|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-28|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-29|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-30|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-31|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-32|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-33|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-34|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-35|35|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-36|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-37|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-38|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-39|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-40|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-41|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-42|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-43|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-44|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-45|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-46|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-47|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-48|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-49|35|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-50|35|1|n/a|n/a|n/a|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-51|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-52|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-53|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-54|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-55|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-56|35|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-57|35|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-35|n/a,TAB 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|58 (58 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-35-58|35|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-1|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-2|36|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-3|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-4|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-5|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-6|36|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-7|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-8|36|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-9|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-10|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-11|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-12|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-13|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-14|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-15|36|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-16|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-17|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-18|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-19|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-20|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-21|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-22|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-23|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-24|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-25|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-26|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-27|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-28|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-29|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-30|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-31|36|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-32|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-33|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-34|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-35|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-36|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-37|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-38|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-39|36|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-40|36|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-41|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-42|36|1|n/a|n/a|n/a|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-43|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-44|36|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-45|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-46|36|1|Neoplasia benign|Bone among musculo-skeletal system diseases|b|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-47|36|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-48|36|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-49|36|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-36|n/a,TAC KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-36-50|36|1|n/a|n/a|n/a|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-1|37|1|n/a|n/a|n/a|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-2|37|1|n/a|n/a|n/a|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-3|37|1|n/a|n/a|n/a|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-4|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-5|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-6|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-7|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-8|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-9|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-10|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-11|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-12|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-13|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-14|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-15|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-16|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-17|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-18|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-19|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-20|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-21|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-22|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-23|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-24|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-25|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-26|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-27|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-28|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-29|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-30|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-31|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-32|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-33|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-34|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-35|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-36|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-37|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-38|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-39|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-40|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-41|37|1|n/a|n/a|n/a|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-42|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-43|37|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-44|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-45|37|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-46|37|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-47|37|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-48|37|1|n/a|n/a|n/a|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-49|37|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-37|n/a,TAC A|1|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|50 (50 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-37-50|37|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-1|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-2|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-3|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-4|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-5|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-6|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-7|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-8|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-9|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-10|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-11|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-12|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-13|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-14|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-15|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-16|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-17|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-18|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-19|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-20|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 507 - mast cell sarcoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-21|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-22|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-23|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-24|38|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-25|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-26|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-27|38|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-28|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-29|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-30|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-31|38|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-32|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-33|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-34|38|1|Neoplasia benign|Bone among musculo-skeletal system diseases|b|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-35|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-36|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-37|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-38|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-39|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-40|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-41|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-42|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-43|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-44|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-45|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-46|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-47|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-48|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-49|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-50|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-51|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-52|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-53|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-54|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-55|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-56|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-57|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-58|38|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-59|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-60|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-61|38|1|Neoplasia benign|Bone among musculo-skeletal system diseases|b|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-62|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-63|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-64|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-65|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-66|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-67|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-68|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-69|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-70|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-71|38|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-72|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-73|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-74|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-75|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-76|38|1|n/a|n/a|n/a|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-77|38|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-78|38|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-79|38|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-38|n/a,TAC 1|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|80 (80 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-38-80|38|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-1|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-2|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-3|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-4|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-5|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-6|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-7|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-8|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-9|39|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-10|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-11|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-12|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-13|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-14|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-15|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-16|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-17|39|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-18|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-19|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-20|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-21|39|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-22|39|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-23|39|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-24|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-25|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-26|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-27|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-28|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-29|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-30|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-31|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-32|39|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-33|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-34|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-35|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-36|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-37|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-38|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-39|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-40|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-41|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-42|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-43|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-44|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-45|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-46|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-47|39|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-48|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-49|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-50|39|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-51|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-52|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-53|39|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-54|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-55|39|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-56|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-57|39|1|n/a|n/a|n/a|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-58|39|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-59|39|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-39|n/a,TAC 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|60 (60 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-39-60|39|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-1|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-2|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-3|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-4|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-5|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-6|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-7|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-8|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-9|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-10|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-11|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-12|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-13|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-14|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-15|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-16|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-17|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-18|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-19|40|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-20|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-21|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-22|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-23|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-24|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-25|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-26|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-27|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-28|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-29|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-30|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-31|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-32|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-33|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-34|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-35|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-36|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-37|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-38|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-39|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-40|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-41|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-42|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-43|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-44|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-45|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-46|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-47|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-48|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-49|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-50|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-51|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-52|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-53|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-54|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-55|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-56|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-57|40|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-58|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-59|40|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-60|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-61|40|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-62|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-63|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-64|40|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-65|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-66|40|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-67|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-68|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-69|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-70|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-71|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-72|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-73|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-74|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-75|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-76|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-77|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-78|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|1|112|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-79|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-1|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-2|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-3|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-4|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-5|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-6|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-7|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-8|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-9|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-10|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-11|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-12|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-13|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-14|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-15|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-16|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-17|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-18|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-19|40|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-20|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-21|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-22|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-23|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-24|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-25|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-26|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-27|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-28|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-29|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-30|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-31|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-32|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-33|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-34|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-35|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-36|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-37|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-38|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-39|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-40|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-41|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-42|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-43|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-44|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-45|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-46|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-47|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-48|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-49|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-50|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-51|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-52|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-53|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-54|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-55|40|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-56|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-57|40|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-58|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-59|40|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-60|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-61|40|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-62|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-63|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-64|40|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-65|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-66|40|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-67|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-68|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-69|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-70|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-71|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-72|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-73|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-74|40|1|n/a|n/a|n/a|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-75|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-76|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-77|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-78|40|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-40|n/a,TAC 1A|2|119|azacytidine|1|becquerels per g animal|Injection, intraperitoneal|35 inject. in 35 weeks|79 (79 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-40-79|40|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-1|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-2|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-3|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-4|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-5|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-6|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-7|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-8|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-9|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-10|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-11|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-12|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-13|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-14|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-15|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-16|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-17|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-18|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-19|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-20|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-21|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-22|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-23|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-24|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-25|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-26|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-27|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-28|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-29|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-30|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-31|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-32|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-33|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-34|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-35|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-36|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-37|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-38|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-39|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-40|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-41|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-42|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-43|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-44|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-45|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-46|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-47|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-48|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-49|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-50|41|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-51|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-52|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-53|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-54|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-55|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-56|41|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-57|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-58|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-59|41|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-1|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-2|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-3|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-4|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-5|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-6|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-7|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-8|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-9|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-10|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-11|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-12|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-13|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-14|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-15|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-16|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-17|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-18|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-19|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-20|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-21|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-22|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-23|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-24|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-25|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-26|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-27|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-28|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-29|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-30|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-31|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-32|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-33|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-34|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-35|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-36|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-37|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-38|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-39|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-40|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-41|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-42|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-43|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-44|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-45|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-46|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-47|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-48|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-49|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-50|41|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-51|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-52|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-53|41|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-54|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-55|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-56|41|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-57|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-58|41|1|n/a|n/a|n/a|
5-8-41|n/a,TAC 5A|2|119|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|35 inject. in 35 weeks|59 (59 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-41-59|41|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-1|42|1|n/a|n/a|n/a|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-2|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-3|42|1|n/a|n/a|n/a|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-4|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-5|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-6|42|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-7|42|1|n/a|n/a|n/a|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-8|42|1|n/a|n/a|n/a|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-9|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-10|42|1|n/a|n/a|n/a|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-11|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-12|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-13|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-14|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-15|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-16|42|1|n/a|n/a|n/a|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-17|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-18|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-42|n/a,TAD B|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-42-19|42|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-1|43|1|n/a|n/a|n/a|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-2|43|1|n/a|n/a|n/a|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-3|43|1|n/a|n/a|n/a|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-4|43|1|n/a|n/a|n/a|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-5|43|1|n/a|n/a|n/a|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-6|43|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-7|43|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-8|43|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-9|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-10|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-11|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-12|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-13|43|1|n/a|n/a|n/a|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-14|43|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-15|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-16|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-17|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-18|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-19|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-20|43|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-21|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-22|43|1|n/a|n/a|n/a|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-23|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-24|43|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-25|43|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-26|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-27|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-28|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-29|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-43|n/a,TAA B|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-43-30|43|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-1|44|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-2|44|1|n/a|n/a|n/a|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-3|44|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-4|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-5|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-6|44|1|n/a|n/a|n/a|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-7|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-8|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-9|44|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-10|44|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-11|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-12|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-13|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-14|44|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-15|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-16|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-17|44|1|n/a|n/a|n/a|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-18|44|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-44|n/a,TAD C|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|19 (19 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-44-19|44|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-1|45|1|n/a|n/a|n/a|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-2|45|1|n/a|n/a|n/a|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-3|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-4|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-5|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-6|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-7|45|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-8|45|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-9|45|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-10|45|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-11|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-12|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-13|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-14|45|1|n/a|n/a|n/a|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-15|45|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-16|45|1|n/a|n/a|n/a|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-17|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-18|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-19|45|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-20|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-21|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-22|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-23|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-24|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-25|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-45|n/a,TAA C|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|26 (26 in ERA)|Mouse|Mouse, CBA|Female|Young Adult|full pathology|5-8-45-26|45|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-1|46|1|n/a|n/a|n/a|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-2|46|1|n/a|n/a|n/a|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-3|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-4|46|1|n/a|n/a|n/a|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-5|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-6|46|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-7|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-8|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-9|46|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-10|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-11|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-12|46|1|n/a|n/a|n/a|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-13|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-14|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-15|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-16|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-17|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-18|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-19|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-20|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-21|46|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-22|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-23|46|1|n/a|n/a|n/a|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-24|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-25|46|1|n/a|n/a|n/a|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-26|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-27|46|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-28|46|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-46|n/a,TAD CL|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|29 (29 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-46-29|46|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-1|47|1|n/a|n/a|n/a|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-2|47|1|n/a|n/a|n/a|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-3|47|1|n/a|n/a|n/a|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-4|47|1|n/a|n/a|n/a|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-5|47|1|n/a|n/a|n/a|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-6|47|1|n/a|n/a|n/a|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-7|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-8|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-9|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-10|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-11|47|1|n/a|n/a|n/a|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-12|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-13|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-14|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-15|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-16|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-17|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-18|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-19|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-20|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-21|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-22|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-23|47|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-24|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-25|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-26|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-27|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-28|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-29|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-47|n/a,TAA CL|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, C57BL|Female|Young Adult|full pathology|5-8-47-30|47|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-1|48|1|n/a|n/a|n/a|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-2|48|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-3|48|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-4|48|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-5|48|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-6|48|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-7|48|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-8|48|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-9|48|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-10|48|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-11|48|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-12|48|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-13|48|1|n/a|n/a|n/a|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-14|48|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-15|48|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-16|48|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-17|48|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-18|48|1|n/a|n/a|n/a|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-19|48|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-20|48|1|n/a|n/a|n/a|
5-8-48|n/a,TAD N|1|112|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|21 (21 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-48-21|48|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-1|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-2|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-3|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-4|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-5|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-6|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-7|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-8|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-9|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-10|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-11|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-12|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-13|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-14|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-15|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-16|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-17|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-18|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-19|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-20|49|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-21|49|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-22|49|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-23|49|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-24|49|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-25|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-26|49|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-27|49|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-28|49|1|n/a|n/a|n/a|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-29|49|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-49|n/a,TAA N|1|112|azacytidine|1|milligrams per kg animal|Injection, intraperitoneal|every three weeks|30 (30 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-49-30|49|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-1|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-2|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-3|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-4|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-5|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-6|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-7|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-8|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-9|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-10|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-11|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-12|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-13|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-14|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-15|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-16|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-17|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-18|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-19|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-20|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-21|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-22|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-23|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-24|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-25|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-26|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-27|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-28|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-29|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-30|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-31|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-32|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-33|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-34|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-35|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-36|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-37|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-38|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-39|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-40|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-41|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-42|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-43|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-44|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-45|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-46|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-47|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-48|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-49|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-50|n/a,TC KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-50-50|50|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-1|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-2|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-3|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-4|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-5|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-6|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-7|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-8|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-9|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-10|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-11|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-12|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-13|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-14|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-15|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-16|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-17|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-18|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-19|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-20|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-21|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-22|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-23|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-24|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-25|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-26|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-27|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-28|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-29|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-30|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-31|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-32|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-33|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-34|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-35|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-36|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-37|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-38|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-39|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-40|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-41|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-42|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-43|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-44|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-45|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-46|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-51|n/a,TC A KO|1|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|47 (47 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|osteosarcoma only|5-8-51-47|51|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-1|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-2|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-3|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-4|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-5|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-6|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-7|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-8|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-9|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-10|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-11|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-12|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-13|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-14|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-15|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-16|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-17|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-18|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-19|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-20|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-21|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-22|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-23|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-24|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-25|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-26|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-27|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-28|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-29|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-30|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-31|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-32|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-33|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-34|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-35|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-36|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-37|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-38|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-39|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-40|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-41|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-42|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-43|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-44|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-45|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-46|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-47|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-48|52|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-52|n/a,TC 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-52-49|52|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-1|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-2|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-3|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-4|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-5|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-6|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-7|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-8|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-9|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-10|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-11|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-12|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-13|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-14|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-15|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-16|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-17|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-18|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-19|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-20|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-21|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-22|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-23|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-24|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-25|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-26|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-27|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-28|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-29|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-30|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-31|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-32|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-33|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-34|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-35|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-36|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-37|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-38|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-39|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-40|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-41|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-42|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-43|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-44|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-45|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-46|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-47|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-48|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-49|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-50|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-1|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-2|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-3|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-4|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-5|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-6|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-7|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-8|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-9|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-10|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-11|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-12|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-13|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-14|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-15|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-16|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-17|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-18|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-19|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-20|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-21|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-22|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-23|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-24|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-25|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-26|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-27|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-28|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-29|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-30|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-31|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-32|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-33|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-34|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-35|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-36|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-37|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-38|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-39|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-40|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-41|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-42|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-43|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-44|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-45|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-46|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-47|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-48|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-49|53|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-53|n/a,TC A5|2|122|cyclophosphamide|60|milligrams per kg animal|Injection, intraperitoneal|12 monthly injections|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Juvenile|osteosarcoma only|5-8-53-50|53|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-1|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-2|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-3|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-4|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-5|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-6|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-7|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-8|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-9|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-10|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-11|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-12|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-13|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-14|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-15|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-16|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-17|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-18|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-19|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-20|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-21|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-22|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-23|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-24|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-25|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-26|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-27|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-28|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-29|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-30|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-31|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-32|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-33|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-34|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-35|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-36|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-37|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-38|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-39|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-40|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-41|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-42|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-43|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-44|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-45|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-46|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-47|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-48|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-54|n/a,TCB KO|1|30|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-54-49|54|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-1|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-2|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-3|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-4|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-5|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-6|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-7|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-8|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-9|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-10|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-11|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-12|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-13|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-14|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-15|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-16|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-17|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-18|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-19|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-20|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-21|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-22|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-23|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-24|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-25|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-26|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-27|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-28|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-29|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-30|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-31|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-32|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-33|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-34|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-35|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-36|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-37|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-38|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-39|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-40|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-41|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-42|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-43|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-44|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-45|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-46|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-47|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-48|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-49|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-50|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-51|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-52|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-53|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-54|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-55|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-56|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-57|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-58|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-59|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-60|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-61|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-62|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-63|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-64|55|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-65|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-66|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-67|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-68|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-55|n/a,TCB 5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|69 (69 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-55-69|55|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-1|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-2|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-3|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-4|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-5|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-6|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-7|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-8|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-9|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-10|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-11|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-12|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-13|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-14|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-15|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-16|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-17|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-18|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-19|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-20|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-21|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-22|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-23|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-24|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-25|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-26|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-27|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-28|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-29|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-30|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-31|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-32|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-33|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-34|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-35|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-36|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-37|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-38|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-39|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-40|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-41|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-42|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-43|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-44|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-45|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-46|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-47|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-48|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-49|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-50|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-51|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-52|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-53|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-54|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-55|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-56|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-57|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-58|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-59|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-60|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-61|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-62|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-63|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-64|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-65|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-66|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-67|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-68|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-69|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-70|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-71|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-72|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-73|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|1|30|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-74|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-1|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-2|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-3|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-4|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-5|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-6|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-7|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-8|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-9|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-10|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-11|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-12|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-13|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-14|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-15|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-16|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-17|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-18|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-19|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-20|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-21|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-22|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-23|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-24|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-25|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-26|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-27|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-28|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-29|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-30|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-31|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-32|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-33|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-34|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-35|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-36|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-37|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-38|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-39|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-40|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-41|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-42|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-43|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-44|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-45|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-46|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-47|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-48|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-49|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-50|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-51|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-52|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-53|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-54|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-55|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-56|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-57|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-58|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-59|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-60|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-61|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-62|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-63|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-64|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-65|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-66|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-67|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-68|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-69|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-70|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-71|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-72|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-73|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|2|31|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-74|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-1|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-2|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-3|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-4|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-5|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-6|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-7|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-8|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-9|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-10|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-11|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-12|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-13|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-14|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-15|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-16|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-17|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-18|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-19|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-20|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-21|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-22|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-23|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-24|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-25|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-26|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-27|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-28|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-29|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-30|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-31|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-32|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-33|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-34|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-35|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-36|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-37|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-38|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-39|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-40|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-41|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-42|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-43|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-44|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-45|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-46|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-47|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-48|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-49|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-50|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-51|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-52|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-53|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-54|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-55|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-56|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-57|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-58|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-59|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-60|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-61|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-62|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-63|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-64|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-65|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-66|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-67|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-68|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-69|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-70|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-71|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-72|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-73|56|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-56|n/a,TCB C5|3|60|cyclophosphamide|150|milligrams per kg animal|Injection, intraperitoneal|n/a|74 (74 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|osteosarcoma only|5-8-56-74|56|1|Other deterministic changes|Bone among musculo-skeletal system diseases|o|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-1|57|1|n/a|n/a|n/a|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-2|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-3|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-4|57|1|n/a|n/a|n/a|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-5|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-6|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-7|57|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-8|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-9|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-10|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-11|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-12|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-13|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-14|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-15|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-16|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-17|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-18|57|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone|b,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-19|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-20|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-21|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-22|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-23|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-24|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-25|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-26|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-27|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-28|57|1|n/a|n/a|n/a|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-29|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-30|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-31|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-32|57|1|n/a|n/a|n/a|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-33|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-34|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-35|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-36|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-37|57|1|n/a|n/a|n/a|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-38|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-39|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-40|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-41|57|1|n/a|n/a|n/a|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-42|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-43|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-44|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-45|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-46|57|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-47|57|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-48|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-49|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-57|n/a,TD KO|1|28|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-57-50|57|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-1|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-2|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-3|58|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-4|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-5|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-6|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-7|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-8|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-9|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-10|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-11|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-12|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-13|58|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-14|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-15|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-16|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-17|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-18|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-19|58|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-20|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-21|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-22|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-23|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-24|58|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-25|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-26|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-27|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-28|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-29|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-30|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-31|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-32|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-33|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-34|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-35|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-36|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-37|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-38|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-39|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-40|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-41|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-42|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-43|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-44|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-45|58|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-46|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-47|58|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-48|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-49|58|1|n/a|n/a|n/a|
5-8-58|n/a,TD D|1|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-58-50|58|1|n/a|n/a|n/a|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-1|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-2|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-3|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-4|59|1|n/a|n/a|n/a|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-5|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-6|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-7|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-8|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-9|59|1|n/a|n/a|n/a|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-10|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-11|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-12|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-13|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-14|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-15|59|1|n/a|n/a|n/a|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-16|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-17|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-18|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-19|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-20|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-21|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-22|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-23|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-24|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-25|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-26|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-27|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-28|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-29|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-30|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-31|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-32|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-33|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-34|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-35|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-36|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-37|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-38|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-39|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-40|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-41|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-42|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-43|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-44|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-45|59|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-46|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-47|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-48|59|1|n/a|n/a|n/a|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-49|59|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-59|n/a,TD 5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-59-50|59|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-1|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-2|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-3|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-4|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-5|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-6|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-7|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-8|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-9|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-10|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-11|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-12|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-13|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-14|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-15|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-16|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-17|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-18|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-19|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-20|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-21|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-22|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-23|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-24|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-25|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-26|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-27|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-28|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-29|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-30|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-31|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-32|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-33|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-34|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-35|60|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-36|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-37|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-38|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-39|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-40|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-41|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-42|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-43|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-44|60|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-45|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-46|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-47|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-48|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-49|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|1|28|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-50|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-1|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-2|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-3|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-4|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-5|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-6|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-7|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-8|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-9|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-10|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-11|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-12|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-13|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-14|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-15|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-16|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-17|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-18|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-19|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-20|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-21|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-22|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-23|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-24|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-25|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-26|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-27|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-28|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-29|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-30|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-31|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-32|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-33|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-34|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-35|60|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-36|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-37|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-38|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-39|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-40|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-41|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-42|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-43|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-44|60|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-45|60|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-46|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-47|60|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-48|60|1|n/a|n/a|n/a|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-49|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-60|n/a,TD D5|2|29|daunamycine|6|milligrams per kg animal|Injection, intraperitoneal|6 inject in 6 weeks|50 (50 in ERA)|Mouse|Mouse, BALB/c|Female|Juvenile|full pathology|5-8-60-50|60|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-1|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-2|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-3|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-4|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-5|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-6|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-7|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-8|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-9|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-10|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-11|61|1|n/a|n/a|n/a|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-12|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-13|61|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-14|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-15|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-16|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-17|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-18|61|1|n/a|n/a|n/a|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-19|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-20|61|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-21|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-22|61|1|n/a|n/a|n/a|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-23|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-24|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-25|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-26|61|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-27|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-28|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-29|61|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-30|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-31|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-32|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-33|61|1|n/a|n/a|n/a|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-34|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-35|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-36|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-37|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-38|61|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-39|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-40|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-41|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-42|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-43|61|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-44|61|1|n/a|n/a|n/a|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-45|61|1|n/a|n/a|n/a|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-46|61|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-47|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-48|61|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-61|n/a,TY KO|1|n/a|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-61-49|61|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-1|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-2|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-3|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-4|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-5|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-6|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-7|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-8|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-9|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-10|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-11|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-12|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-13|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-14|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-15|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-16|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-17|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-18|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-19|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-20|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-21|62|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-22|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-23|62|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-24|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-25|62|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-26|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-27|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-28|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-29|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-30|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-31|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-32|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-33|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-34|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-35|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-36|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-37|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-38|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-39|62|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-40|62|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-41|62|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-42|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-43|62|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-44|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-45|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-46|62|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-47|62|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-48|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-49|62|1|n/a|n/a|n/a|
5-8-62|n/a,TY C1|1|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-62-50|62|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-1|63|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-2|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-3|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-4|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-5|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-6|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-7|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-8|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-9|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-10|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-11|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-12|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-13|63|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-14|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-15|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-16|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-17|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-18|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-19|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-20|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-21|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-22|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-23|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-24|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-25|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-26|63|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-27|63|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-28|63|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-29|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-30|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-31|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-32|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-33|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-34|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-35|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-36|63|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-37|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-38|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-39|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-40|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-41|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-42|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-43|63|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-44|63|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-45|63|1|n/a|n/a|n/a|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-46|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-47|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-48|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-49|63|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-63|n/a,TY C2|1|210|cyclosporine A|50|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|50 (50 in ERA)|Mouse|Mouse, NMRI|Female|Adult|full pathology|5-8-63-50|63|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-1|64|1|n/a|n/a|n/a|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-2|64|1|n/a|n/a|n/a|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-3|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-4|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-5|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-6|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-7|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-8|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-9|64|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-10|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-11|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-12|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-13|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-14|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-15|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-16|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-17|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-18|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-19|64|1|Neoplasia systemic|Haematolymphatic system|L|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-20|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-21|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-22|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-23|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-24|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-25|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-26|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-27|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-28|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-29|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-30|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-31|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-32|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-33|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-34|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-35|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-36|64|1|n/a|n/a|n/a|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-37|64|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-38|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-39|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-40|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-41|64|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-42|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-Ret.A  L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-43|64|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-44|64|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-45|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-46|64|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-47|64|1|n/a|n/a|n/a|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-48|64|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-64|n/a,TY T|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-64-49|64|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-1|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-2|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-3|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-4|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-5|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-6|65|1|Neoplasia systemic|Haematolymphatic system|L|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-7|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-8|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-9|65|1|n/a|n/a|n/a|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-10|65|1|Neoplasia systemic|Haematolymphatic system|L|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-11|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-12|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-13|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-14|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-15|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-16|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-17|65|1|n/a|n/a|n/a|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-18|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-19|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-20|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-21|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-22|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-23|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-24|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-25|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-26|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-27|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-28|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-29|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-30|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-31|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-32|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-33|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-34|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-35|65|1|n/a|n/a|n/a|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-36|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-37|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-38|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-39|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-40|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-41|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-42|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-43|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-44|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-45|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-46|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-47|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-48|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-49|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-1|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-2|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-3|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-4|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-5|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-6|65|1|Neoplasia systemic|Haematolymphatic system|L|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-7|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-8|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-9|65|1|n/a|n/a|n/a|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-10|65|1|Neoplasia systemic|Haematolymphatic system|L|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-11|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-12|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-13|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-14|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-15|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-16|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-17|65|1|n/a|n/a|n/a|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-18|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-19|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-20|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-21|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-22|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-23|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-24|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-25|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-26|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-27|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-28|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-29|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-30|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-31|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-32|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-33|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-34|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-35|65|1|n/a|n/a|n/a|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-36|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-37|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-38|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-39|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-40|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-41|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-42|65|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-43|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-44|65|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-45|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-46|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-47|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-48|65|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-65|n/a,TY TC1|2|210|cyclosporine A|10|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-65-49|65|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-1|66|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-2|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-3|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-4|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-5|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-6|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-7|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-8|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-9|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-10|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-11|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-12|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-13|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-14|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-15|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-16|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-17|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-18|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-19|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-20|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-21|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-22|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-23|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-24|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-25|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-26|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-27|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-28|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-29|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-30|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-31|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-32|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-33|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-34|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-35|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-36|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-37|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-38|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-39|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-40|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-41|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-42|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-43|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-44|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-45|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-46|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-47|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-48|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|1|92|Th-227 citrate|37|becquerels per g animal|Injection, intraperitoneal|single injection|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-49|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-1|66|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-2|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-3|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-4|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-5|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-6|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-7|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-8|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-9|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-10|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-11|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-12|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-13|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-14|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-15|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-16|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-17|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-18|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-19|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-20|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-21|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-22|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-23|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-24|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-25|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-26|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-27|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-28|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|M,MPATH: 551 - sarcoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-29|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-30|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-31|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-32|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-33|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-34|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-35|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-36|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-37|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-38|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-39|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-40|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-41|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-42|66|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-43|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-44|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-45|66|1|n/a|n/a|n/a|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-46|66|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-47|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-48|66|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-66|n/a,TY TC2|2|210|cyclosporine A|20|milligrams per kg animal|Ingestion in food or water|weekly for 28 weeks|49 (49 in ERA)|Mouse|Mouse, NMRI|Female|Young Adult|full pathology|5-8-66-49|66|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-1|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-2|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-3|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-4|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-5|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-6|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-7|67|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-8|67|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-9|67|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-10|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-11|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-12|67|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-13|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-14|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-15|67|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-16|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-17|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-18|67|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-19|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-20|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-21|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-22|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|Ret.B-lymphatic Leukemia  L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-23|67|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-24|67|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-25|67|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-26|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-27|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-28|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-29|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-30|67|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-31|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-32|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-33|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-34|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-35|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-36|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-37|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-38|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-39|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-40|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-41|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-42|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-43|67|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-44|67|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-45|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-46|67|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-47|67|1|n/a|n/a|n/a|
5-8-67|n/a,TI KO|1|113|none (controls)|0|unit code not relevant|not applicable or not supplied|n/a|48 (48 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-67-48|67|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-1|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-2|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-3|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-4|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-5|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-6|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-7|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-8|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-9|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-10|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-11|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-12|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-13|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-14|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-15|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-16|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-17|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-18|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-19|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-20|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-21|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-22|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-23|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-24|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-25|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-26|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-27|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-28|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-29|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-30|68|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-31|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-32|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-33|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-34|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-35|68|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-36|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-37|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-38|68|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-39|68|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-40|68|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-41|68|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-42|68|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-43|68|1|n/a|n/a|n/a|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-44|68|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-45|68|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-46|68|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-47|68|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-48|68|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-68|n/a,TI I|1|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|n/a|49 (49 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-68-49|68|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-1|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-2|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-3|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-4|69|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-5|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-6|69|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001459 - bone,MA: 0001459 - bone|b,MPATH: 393 - osteoblastoma,MPATH: 395 - osteofibroma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-7|69|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-8|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-9|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-10|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-11|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-12|69|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-13|69|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-14|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-15|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-16|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-17|69|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-18|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-19|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-20|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-21|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-22|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-23|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-24|69|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-25|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-26|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-27|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-28|69|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-29|69|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-30|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-31|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-32|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-33|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-34|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-35|69|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-36|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-37|69|1|n/a|n/a|n/a|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-38|69|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-39|69|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-40|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-41|69|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-42|69|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-43|69|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-44|69|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-45|69|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-69|n/a,TI 5|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|46 (46 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-69-46|69|1|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|M,MPATH: 549 - carcinoma|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-1|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-2|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-3|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-4|70|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-5|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-6|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-7|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-8|70|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-9|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-10|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-11|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-12|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-13|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-14|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-15|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-16|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-17|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-18|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-19|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-20|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-21|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-22|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-23|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-24|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-25|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-26|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-27|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-28|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-29|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-30|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-31|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-32|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-33|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-34|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-35|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-36|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-37|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-38|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-39|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-40|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-41|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-42|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-43|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-44|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-45|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-46|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|1|112|Th-227 citrate|185|becquerels per g animal|Injection, intraperitoneal|single injection|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-47|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-1|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-2|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-3|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-4|70|1|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-5|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-6|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-7|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-8|70|1|Neoplasia benign|Bone among musculo-skeletal system diseases,MA: 0001487 - mandible|b,MPATH: 572 - ossifying fibroma|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-9|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-10|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-11|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-12|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-13|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-14|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-15|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-16|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-17|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-18|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-19|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-20|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-21|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-22|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-23|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-24|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-25|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-26|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-27|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-28|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-29|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-30|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-31|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-32|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-33|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-34|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-35|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-36|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-37|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-38|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-39|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-40|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-41|70|1|n/a|n/a|n/a|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-42|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-43|70|1|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|L,MPATH: 513 - Lymphoid neoplasms|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-44|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-45|70|1|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|a,MPATH: 218 - neoplasm|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-46|70|1|Neoplasia malignant|Bone among musculo-skeletal system diseases|M|
5-8-70|n/a,TI 5i|2|113|indomethazine|20|milligrams /l drink|Ingestion in food or water|until death|47 (47 in ERA)|Mouse|Mouse, BALB/c|Female|Young Adult|full pathology|5-8-70-47|70|1|n/a|n/a|n/a|
